The Board of Directors of the Company has approved and recommended the payment of final dividend on the equity shares of the Company for the FY 2025-26.
ANURAS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Anupam Rasayan India Ltd reported strong FY2026 standalone revenue of INR 16,755.67 million, up 87% from INR 8,958.99 million in FY2025. Standalone PAT surged 122% to INR 1,613.96 million from INR 726.74 million, with EPS at INR 14.32 vs INR 6.62. The Board recommended final dividend of INR 1.5 per share (15% on INR 10 face value). Consolidated revenue reached INR 23,654.55 million. The company also approved acquisition of up to 74.20% stake in Bliss GVS Pharma Ltd (listed company) and plans to raise INR 160 crore via 16,000 NCDs on private placement basis. Deputy CFO Mr. Vishal Thakkar resigned. Auditors issued unmodified opinion.
Strong financial performance with near doubling of revenue and over 2x PAT growth. Dividend declaration signals confidence. However, increased borrowings for acquisitions and NCD issuance add leverage, requiring monitoring. Resignation of CFO may have short-term sentiment impact.